Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients

Inclusion Criteria: * RA according to American College of Rheumatology (ACR)/European League Against rheumatism (EULAR) 2010 criteria * Disease Activity Score (DAS) 28 ≥ 3.2 * Initiation of a treatment by sub-cutaneous abatacept in combination with methotrexate (MTX), whatever treatment they were receiving before (apart from rituximab (RTX) in the last year) * Patient has signed study consent form Exclusion Criteria: * age \< 18 or \> 85 year * dementia * patients subjects to legal protection measures * Corticosteroids ≥ 10mg/d the day of inclusion * Patient who had a pneumococcal vaccination in the previous 3 years * Last pneumococcal vaccination \< 3 year * rituximab in the last year * History of anaphylactic response to a vaccination * Contraindications to abatacept or methotrexate * Pregnancy or pregnancy wish * Breast feeding * Patient who currently abuse drugs or alcohol * Subject who have received any live vaccines within 3 months of the anticipated first dose of study medication. * Subject who have receive any vaccine within 1 month of the anticipated first dose of the study medication and for all the duration of the study * Patient with contraindication to intramuscular injections * Subject with respiratory insufficiency * Subject at risk for Tuberculosis. * Blood transfusion within the 3 months previous to the study and for all the duration of the study. * Concomitant biologic disease-modifying antirheumatic drug (DMARD) * Within 4 weeks of receiving treatment with any investigational drug. * Patient positive for hepatitis B surface antigen * Patient who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.